Skip to main content

Table 1 Baseline characteristics

From: Inverse association between central obesity and arterial stiffness in Korean subjects with metabolic syndrome: a cross-sectional cohort study

Characteristics No MetS (NCEP-ATP III - / IDF -) (n = 1,608) MetS (NCEP-ATP III +) P
Total (n = 952) With CeO (IDF +) (n = 804) Without CeO (IDF -) (n = 148)
Age (years) 65 (60, 69) 64 (57, 69) 62 ± 8 61 ± 7 <0.001
Male gender (%) 31 36 32 62* 0.004
Smoking (%) 24 32 29 52* <0.001
BMI (kg/m2) 24.0 ± 2.7 26.4 ± 2.9 26.8 ± 2.8 23.9 ± 1.9* <0.001
Waist circumference (cm) 81 ± 8 89 ± 7 90 ± 7 81 ± 6* <0.001
Heart rate (bpm) 66 ± 9 68 ± 10 68 ± 10 70 ± 11 <0.001
SBP (mmHg) 120 ± 14 128 ± 15 128 ± 15 130 ± 15 <0.001
DBP (mmHg) 72 ± 9 77 ± 10 76 ± 10 79 ± 10 <0.001
Antihypertensive medications (%) 29 66 67 66 <0.001
Total cholesterol (mg/dL) 201 ± 36 197 ± 37 197 ± 37 195 ± 36 0.006
Triglycerides (mg/dL) 94 (71, 118) 136 (103, 186) 164 ± 82 210 ± 80* <0.001
HDL cholesterol (mg/dL) 57 (51, 63) 45 (37, 55) 47 ± 13 41 ± 11* <0.001
LDL cholesterol (mg/dL) 110 (83, 127) 106 (83, 130) 121 ± 34 117 ± 33 0.096
Lipid lowering medications (%) 27 31 31 27 0.034
Creatinine (mg/dL) 0.78 (0.63, 0.95) 0.81 (0.68, 0.93) 0.79 ± 0.19 0.87 ± 0.19* <0.001
Fasting glucose (mg/dL) 121 (105, 137) 125 (108, 143) 109 ± 24 114 ± 27 <0.001
Diabetes (%) 8 30 30 30 <0.001
Antidiabetic treatment (%) 7 25 82 84 <0.001
Duration of diabetes (months) 92 (44, 202) 92 (44, 152) 110 ± 85 107 ± 87 0.177
baPWV (cm/s) 1576 (1414, 1760) 1625 (1452, 1864) 1578 ± 270 1654 ± 315 <0.001
  1. Continuous variables are expressed as mean ± SD or median [interquartile]. Categorical variables are presented as percentages. baPWV, brachial-ankle pulse wave velocity; BMI, body mass index; CeO, central obesity; DBP, diastolic blood pressure; HDL, high-density lipoprotein; IDF, International Diabetes Federation; LDL, low-density lipoprotein; MetS, metabolic syndrome; NCEP-ATP III, National Cholesterol Education Program-Adult Treatment Panel III; SBP, systolic blood pressure. *p <0.001 vs. NCEP-ATP III + / IDF +, p <0.01 vs. NCEP-ATP III + / IDF +, p <0.05 vs. NCEP-ATP III + / IDF +.